Change of serum levels of pentraxin-3 and syndecan-4 in children with chronic heart failure.
- Author:
Feng-Hua ZHANG
1
;
Xiao-Lin ZHAO
1
;
Song FENG
1
;
Jin-Dou AN
1
Author Information
1. Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
Child;
Chronic Disease;
Heart Failure;
Humans;
Natriuretic Peptide, Brain;
Peptide Fragments;
Stroke Volume;
Syndecan-4;
Ventricular Function, Left
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(5):513-518
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the change and significance of serum pentraxin-3 (PTX-3) and syndecan-4 in children with chronic heart failure (CHF).
METHODS:A total of 40 children with CHF who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Zhengzhou University were enrolled as the heart failure group, and 30 children who underwent physical examination in the outpatient service during the same period of time were enrolled as the control group. The serum levels of PTX-3, syndecan-4, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were compared between the two groups.
RESULTS:The children with CHF had significant reductions in the serum levels of PTX-3, syndecan-4, and NT-proBNP after treatment. The levels of these markers in children with CHF were significantly higher than the control group before and after treatment (
CONCLUSIONS:Serum PTX-3 and syndecan-4 may be involved in the development and progression of ventricular remodeling in children with CHF and may be used as markers for the diagnosis, cardiac function grading, and treatment outcome evaluation of children with heart failure.
